RGNX
REGENXBIO Inc.
Next earnings Aug 5, 2026 (after close) · consensus $0.22 EPS, $121M rev
Last earnings -37.8% on 2026-05-14
$10.48
▲ +2.34%$10.48▲ +33.33%
over 1Y
L $5.65EODHDH $15.98
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.3%
1W+15.5%
1M+56.7%
3M+35.1%
YTD-22.8%
1Y+33.3%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 19 analysts
Buy
Revenue grew 104.5% YoY; but unprofitable (net margin -113.8%).
Revenue (FY2025) $170M · FY2025
REGENXBIO Inc. shows $170M in FY2025 revenue (+104.5% YoY), a -113.8% net margin, and -188.7% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $470M | $113M | $90.2M | $83.3M | $170M |
| Gross profit | — | — | — | — | — |
| Operating income | $160M | -$263M | -$268M | -$233M | -$161M |
| Net income | $128M | -$280M | -$263M | -$227M | -$194M |
| Diluted EPS | $2.91 | -$6.50 | -$6.02 | -$4.59 | -$3.76 |
| Net margin | 27.2% | -248.7% | -292.0% | -272.5% | -113.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$506M
EV / EBITDA—
EV / Sales3.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-35.8%
FCF yield-23.4%
Quality & risk
ROIC (est.)-124.0%
Free cash flow-$126M
Total debt—
Net cash$34.5M
Altman Z-Score-2.92 distress
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+3.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗SCHEDULE 13G/AFiling2026-06-04open ↗SC TO-IFiling2026-06-03open ↗8-KPeriod ending 2026-05-292026-06-03open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗
Frequently asked
- Is REGENXBIO Inc. (RGNX) a buy?
- RGNX currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 104.5% YoY; but unprofitable (net margin -113.8%).
- What is REGENXBIO Inc.'s quality score?
- RGNX scores 54.96078431372548/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001590877, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 6:10:11 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.